Regulatory Guidance
Current regulatory status of research peptides in key jurisdictions. This information is educational and subject to change — always verify with current regulatory sources.
United States (FDA)
The FDA significantly restricted research peptide compounding in 2024 under 503A/503B pharmacy regulations. Several key peptides — including BPC-157, TB-500, and Epithalon — were added to the "Demonstrably Difficult to Compound" (DDIT) list or are otherwise restricted from compounding.
FDA-Approved Peptides Include:
- Approved Semaglutide (Ozempic, Wegovy)
- Approved Tirzepatide (Mounjaro, Zepbound)
- Approved Tesamorelin (Egrifta)
- Approved Sermorelin (various)
- Approved Thymosin Alpha-1 (Zadaxin — limited)
- Research Only BPC-157 (no human approval)
- Research Only TB-500 (no human approval)
- Research Only Ipamorelin/CJC-1295 (compounding restricted)
Australia (TGA)
In Australia, most therapeutic peptides are classified as Schedule 4 (Prescription Only Medicine) under the Therapeutic Goods Administration (TGA). Some are listed on the Australian Register of Therapeutic Goods (ARTG), while others exist in a compounding-access framework.
Key Points:
- GLP-1 agonists require prescription and are PBS-listed for specific indications
- BPC-157 and TB-500 are not TGA-approved but can be compounded under S4 with a prescription
- Peptides for non-human use (research animals) have fewer restrictions
- Importing unapproved therapeutic goods requires a Special Access Scheme (SAS) application
European Union (EMA)
Regulatory status across EU member states varies significantly. The European Medicines Agency (EMA) centrally authorises some peptide drugs, but research peptide access for clinical research is governed by national regulations.
Key Points:
- Semaglutide and liraglutide are EMA-approved for specific indications
- Research peptides (BPC-157, TB-500) exist in a legal grey area in most EU countries
- Germany, Czech Republic, and some other countries have more permissive research compound frameworks
- Clinical research requires Ethics Committee approval and national competent authority notification
Canada (Health Canada)
Health Canada regulates therapeutic peptides under the Food and Drugs Act. Most research peptides are not approved as drugs but are not explicitly prohibited for research purposes when obtained through legitimate channels.
Key Points:
- Approved GLP-1 agonists are available by prescription through normal channels
- Unapproved research peptides can be imported under the Personal Importation Policy (limited quantities)
- Research use in licensed facilities follows separate guidelines
- Selling unapproved drugs in Canada is prohibited under the Food and Drugs Act
A Note on "Research Use Only" Compounds
Many peptides sold commercially are labelled "For Research Use Only" (RUO). This designation means the product is not intended for human consumption, is not manufactured under pharmaceutical GMP standards, and has not undergone the regulatory review process for human use. Researchers should be aware that RUO peptides may vary significantly in purity, concentration accuracy, and sterility compared to pharmaceutical-grade compounded products.
Review Safety Guidelines →